Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 155 clinical trials
4SCAR-CD44v6 T Cell Therapy Targeting Cancer

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers. The study also aims to learn more about the function of the CD44v6 CAR-T cells and their persistency in the patients.

  • 0 views
  • 19 Feb, 2024
PSMA-specific CAR-T Cell Therapy

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor. Another goal of the study is to learn more about the function of the PSMA CAR-T cells and their persistency in the patients.

  • 0 views
  • 19 Feb, 2024
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who are circulating tumor DNA (ctDNA) positive following surgical resection and have received standard-of-care adjuvant platinum-doublet chemotherapy.

cancer
immunomodulators
hepatitis
non-small cell lung cancer
small cell lung cancer
  • 0 views
  • 19 Feb, 2024
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC neoSCORE

This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.

platelet count
pulmonary disease
g-csf
hepatitis
liver disease
  • 0 views
  • 19 Feb, 2024
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic, colon and lung cancers.

measurable disease
cancer
hair thinning
cancer therapy
pancreatic cancer
  • 0 views
  • 19 Feb, 2024
Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients

The study is devoted to the comparative analysis of the data received in patients with COVID-19 lung pathology using the method of probe-based confocal laser endomicroscopy of distal airways and two reference methods: high resolution computed tomography and morphology (in some patients).

pneumonia
critical illness
ct scan
chronic obstructive pulmonary disease
critically ill
  • 0 views
  • 19 Feb, 2024
A081801 / RLUN20119 / ALCHEMIST-IO (ACCIO) / Yuhchyau Chen  

Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB IIIA or IIIB non-small cell lung cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver and brain.

brain metastasis
ipilimumab
cancer
corticosteroid therapy
metastasis
  • 0 views
  • 19 Feb, 2024
Carotid Doppler and EEOT for Fluid Responsiveness Prediction

In clinical practice, functional hemodynamic tests (FHT) consisting of maneuvers that affect cardiac function and/or heart-lung interaction, have been introduced in order to identify fluid responders and non-responders without fluid challenge administration.

stroke
  • 0 views
  • 19 Feb, 2024
Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection

An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection

cough
fever
dyspnea
covid-19
pneumonia
  • 0 views
  • 19 Feb, 2024